Botanical species · safety record

Phaseolus lunatus

The EFSA Compendium of Botanicals holds 24 constituent measurements and 3 adverse-effect records for Phaseolus lunatus. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Phaseolus lunatus L.

24Constituent measurements
3Safety records
7Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Cyanogenic glycosides6
  • Daidzein2
  • Formononetin2
  • Genistein2
  • Linamarin2
  • Lotaustralin2
  • Phytic acid2
  • Secoisolarisiresinol2
  • Biochanin-a1
  • Coumestrol1

Plant parts

  • Seed23
  • Leaves4

Preparations

  • Solvent extraction24

Effect types

  • Digestive2
  • Not reported1

Target tissues

  • Digestive1
  • Stomach1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
Cyanogenic glycosidesLeavesSolvent extraction≥ 0.8 Microgram/gramUnspecifiedResolve DOI
Cyanogenic glycosidesLeavesSolvent extraction≥ 3.3 Microgram/gramUnspecifiedResolve DOI
Cyanogenic glycosidesLeavesSolvent extraction≤ 10.4 Microgram/gramUnspecifiedResolve DOI
Cyanogenic glycosidesLeavesSolvent extraction≤ 8.9 Microgram/gramUnspecifiedResolve DOI
Cyanogenic glycosidesSeedSolvent extraction≥ 0.6 Microgram/gramUnspecifiedResolve DOI
Cyanogenic glycosidesSeedSolvent extraction≤ 1 Microgram/gramUnspecifiedResolve DOI
Hydrocyanic acidSeedSolvent extraction32 Milligram/kilogramColorimetry, Spectroscopy (Spectrometry) and PhotometryResolve DOI
LinamarinSeedSolvent extraction≥ 14 Milligram/gramChromatographic testsResolve DOI
LinamarinSeedSolvent extraction≤ 26 Milligram/gramChromatographic testsResolve DOI
LotaustralinSeedSolvent extraction≥ 220 Microgram/gramChromatographic testsResolve DOI
LotaustralinSeedSolvent extraction≤ 790 Microgram/gramChromatographic testsResolve DOI
Phytic acidSeedSolvent extraction≤ 11.6 Microgram/gramColorimetry, Spectroscopy (Spectrometry) and PhotometryResolve DOI
Phytic acidSeedSolvent extraction≥ 8 Microgram/gramColorimetry, Spectroscopy (Spectrometry) and PhotometryResolve DOI
Biochanin-aSeedSolvent extraction≤ 2.7 Microgram/100 gramGC-MSNo resolvable identifier
CoumestrolSeedSolvent extraction≤ 10 Microgram/100 gramGC-MSNo resolvable identifier
DaidzeinSeedSolvent extraction≥ 12.2 Microgram/100 gramGC-MSNo resolvable identifier
DaidzeinSeedSolvent extraction≤ 89 Microgram/100 gramGC-MSNo resolvable identifier
FormononetinSeedSolvent extraction≤ 12.4 Microgram/100 gramGC-MSNo resolvable identifier
FormononetinSeedSolvent extraction≥ 9 Microgram/100 gramGC-MSNo resolvable identifier
GenisteinSeedSolvent extraction≥ 10.6 Microgram/100 gramGC-MSNo resolvable identifier
GenisteinSeedSolvent extraction≤ 19.2 Microgram/100 gramGC-MSNo resolvable identifier
MatairesinolSeedSolvent extractionGC-MSNo resolvable identifier
SecoisolarisiresinolSeedSolvent extraction≥ 158 Microgram/100 gramGC-MSNo resolvable identifier
SecoisolarisiresinolSeedSolvent extraction≤ 185 Microgram/100 gramGC-MSNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
DigestiveStomachSeedRat (as animal)SubchronicResolve DOI
DigestiveDigestiveSeedHuman (as organism)Case reportNo resolvable identifier
Not reportedSeedHuman (as organism)Case reportNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Mazur, Witold M., Duke, James A., Wahala, Kristiina., Rasku, Sirpa., Adlercreutz, Herman. Isoflavonoids and lignans in legumes: nutritional and health aspects in humans. Journal of nutritional biochemistry, 1998, vol. 9, no. 4, p. 193-200.
  2. Guignard, L. The hydrogen cyanide supplying bean (Phaseolus Lunatus). Historical, botanical and chemical study. New procedure for the proof of hydrocyanic acid. machine translation . Bull. des sciences pharmacol., 1906, vol. 13, p. 129-38.
  3. Betancur-Ancona, D., Segura-Campos, M., Rosado-Rubio, G., Franco, L.S., Chel-Guerrero, L. Chemical composition and anti-nutritional factors in five tropical legume seeds. Beans: nutrition, consumption and health, 2012, p. 117-141.
  4. Jaff�, W.G. Toxische und Wachstumshemmende Faktoren in Bohnen. Qualitas plantarum et materiae vegetabiles, 1969, vol. 17, no. 2, p. 113-130. DOI
  5. Laurena, Antonio C., Revilleza, Ma. Jamela R., Mendona, Evelyn Mae T. Polyphenols, Phytate, Cyanogenic Glycosides, and Trypsin Inhibitor Activity of Several Philippine Indigenous Food Legumes. Journal of Food Composition and Analysis, 1994, vol. 7, no. 3, p. 194-202. DOI
  6. Shlichta, J. Gwen., Glauser, Gaetan., Benrey, Betty. Variation in Cyanogenic Glycosides Across Populations of Wild Lima Beans (Phaseolus lunatus) Has No Apparent Effect on Bruchid Beetle Performance . Journal of chemical ecology, 2014, vol. 40, no. 5, p. 468-475. DOI
  7. Cressey, P., Saunders, D., Goodman, J. Cyanogenic glycosides in plant-based foods available in New Zealand. Food additives and contaminants - part a chemistry, analysis, control, exposure and risk assessment, 2013, vol. 30, no. 11, p. 1946-1953. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue